Petros W P, Peters W P
Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Bone Marrow Transplant. 1993;11 Suppl 2:36-8.
The emergence of novel medical therapies has impacted considerably on the treatment of a number of diseases. However, the application of these new modalities is often restricted by cost concerns. Haematopoietic growth factors (HGFs) accelerate haematopoietic reconstitution and may be used in conjunction with bone marrow transplantation (BMT) allowing dose intensification. It is hoped that the use of HGFs to reduce morbidity and supportive care requirements may lead to cost savings. Studies to assess the cost-effectiveness of G-CSF and GM-CSF are currently being conducted. In one analysis in the USA, the use of HGF alone following BMT did not significantly reduce overall costs; however, when HGF-primed progenitor cells were used in conjunction with BMT, a quicker neutrophil recovery was noted, which translated into shorter hospitalisation and, therefore, lower costs. These results indicate the importance of economic analyses, and in the future such cost-effectiveness studies will become an integral component of research development.
新型药物疗法的出现对多种疾病的治疗产生了重大影响。然而，这些新方法的应用常常受到成本问题的限制。造血生长因子（HGFs）可加速造血重建，并可与骨髓移植（BMT）联合使用，从而实现剂量强化。人们希望使用HGFs来降低发病率和支持治疗需求可能会节省成本。目前正在开展评估G-CSF和GM-CSF成本效益的研究。在美国的一项分析中，BMT后单独使用HGF并不能显著降低总体成本；然而，当将经HGF预处理的祖细胞与BMT联合使用时，中性粒细胞恢复更快，这意味着住院时间缩短，因此成本降低。这些结果表明了经济分析的重要性，未来此类成本效益研究将成为研究发展的一个组成部分。
